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Time, pattern, and outcome of medulloblastoma relapse and 
their association with tumour biology at diagnosis and 
therapy: a multicentre cohort study 
Rebecca M Hill, Stacey Richardson, Edward C Schwalbe, Debbie Hicks, Janet C Lindsey, Stephen Crosier, Gholamreza Rafiee, Yura Grabovska, 
Stephen B Wharton, Thomas S Jacques, Antony Michalski, Abhijit Joshi, Barry Pizer, Daniel Williamson, Simon Bailey, Steven C Clifford
Summary
Background Disease relapse occurs in around 30% of children with medulloblastoma, and is almost universally fatal. 
We aimed to establish whether the clinical and molecular characteristics of the disease at diagnosis are associated 
with the nature of relapse and subsequent disease course, and whether these associations could inform clinical 
management.
Methods In this multicentre cohort study we comprehensively surveyed the clinical features of medulloblastoma 
relapse (time to relapse, pattern of relapse, time from relapse to death, and overall outcome) in centrally reviewed 
patients who relapsed following standard upfront therapies, from 16 UK Children’s Cancer and Leukaemia Group 
institutions and four collaborating centres. We compared these relapse-associated features with clinical and molecular 
features at diagnosis, including established and recently described molecular features, prognostic factors, and 
treatment at diagnosis and relapse.
Findings 247 patients (175 [71%] boys and 72 [29%] girls) with medulloblastoma relapse (median year of diagnosis 
2000 [IQR 1995–2006]) were included in this study. 17 patients were later excluded from further analyses because they 
did not meet the age and treatment criteria for inclusion. Patients who received upfront craniospinal irradiation 
(irradiated group; 178 [72%] patients) had a more prolonged time to relapse compared with patients who did not 
receive upfront craniospinal irradiation (non-irradiated group; 52 [21%] patients; p<0·0001). In the non-irradiated 
group, craniospinal irradiation at relapse (hazard ratio [HR] 0·27, 95% CI 0·11–0·68) and desmoplastic/nodular 
histology (0·23, 0·07–0·77) were associated with prolonged time to death after relapse, MYC amplification was 
associated with a reduced overall survival (23·52, 4·85–114·05), and re-resection at relapse was associated with longer 
overall survival (0·17, 0·05–0·57). In the irradiated group, patients with MBGroup3 tumours relapsed significantly more 
quickly than did patients with MBGroup4 tumours (median 1·34 [0·99–1·89] years vs 2·04 [1·39–3·42 years; p=0·0043). 
Distant disease was prevalent in patients with MBGroup3 (23 [92%] of 25 patients) and MBGroup4 (56 [90%] of 62 patients) 
tumour relapses. Patients with distantly-relapsed MBGroup3 and MBGroup4 displayed both nodular and diffuse patterns of 
disease whereas isolated nodular relapses were rare in  distantly-relapsed MBSHH (1 [8%] of 12 distantly-relapsed MBSHH 
were nodular alone compared with 26 [34%] of 77 distantly-relapsed MBGroup3 and MBGroup4). In MBGroup3 and MBGroup4, 
nodular disease was associated with a prolonged survival after relapse (HR 0·42, 0·21–0·81). Investigation of second-
generation MBGroup3 and MBGroup4 molecular subtypes refined our understanding of heterogeneous relapse 
characteristics. Subtype VIII had prolonged time to relapse and subtype II had a rapid time from relapse to death. 
Subtypes II, III, and VIII developed a significantly higher incidence of distant disease at relapse whereas 
subtypes V and VII did not (equivalent rates to diagnosis).
Interpretation This study suggests that the nature and outcome of medulloblastoma relapse are biology and therapy-
dependent, providing translational opportunities for improved disease management through biology-directed disease 
surveillance, post-relapse prognostication, and risk-stratified selection of second-line treatment strategies.
Funding Cancer Research UK, Action Medical Research, The Tom Grahame Trust, The JGW Patterson Foundation, 
Star for Harris, The Institute of Child Health - Newcastle University - Institute of Child Health High-Risk Childhood 
Brain Tumour Network (co-funded by The Brain Tumour Charity, Great Ormond Street Children’s Charity, and 
Children with Cancer UK).
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4·0 license.
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Introduction 
Over the past decade, advances have been made in the 
understanding of medulloblastoma biology at diagnosis. 
Four consensus molecular subgroups—WNT (MBWNT), 
SHH (MBSHH), group 3 (MBGroup3), and group 4 (MBGroup4)—
are now recognised and underpin the 2016 WHO 
classification of medulloblastoma (genetically defined as 
WNT-activated; SHH-activated and TP53-mutant and 
SHH-activated and TP53-wildtype; and non-WNT and 
non-SHH [group3 and group4]).1 Molecular profiling of 
a greater number of tumours at diagnosis has led to the 
discovery of second-generation MBGroup3 and MBGroup4 
subtypes.2,3 Furthermore, molecular features have 
prognostic significance and define upfront therapy strat-
ification. For example, molecular features identified in 
international clinical trials (eg, SJMB12 [NCT01878617] 
and SIOP-PNET5-MB [NCT02066220]) have led to 
therapy reduction in groups with a good prognosis (eg, 
MBWNT) and treatment intensification or the use of 
novel therapies for groups at a high risk of relapse and 
mortality (eg, MYC-amplified MBGroup3).
Disease relapse is the most adverse prognostic factor in 
medulloblastoma. Relapses occur in approximately 30% of 
patients and are almost always fatal.4–6 Most patients will 
relapse at distant CNS sites with or without disease in the 
original tumour bed. Individual reports indicate relapse 
can occur more than 5 years after diagnosis, with the 
duration of survival after relapse equally as variable.3–5,7 
Durable remissions following relapse typically cluster in 
younger children (aged <3–5 years) who received 
deferred craniospinal irradiation as salvage therapy.8,9 
Older children (aged >3–5 years) with disease relapse who 
received conventional upfront therapy (neuro surgery, 
craniospinal irradiation, and chemotherapy) are treated 
with various strategies at relapse, including metronomic 
therapy, high-dose chemotherapy, intrathecal medication, 
and re-irradiation, but these approaches are commonly 
unsuccessful (typically <5% long-term survival).6,7,10–13 Of 
note, few studies have attempted to characterise the nature 
of medulloblastoma relapse, its clinical and molecular 
correlates, and their translational potential.5,7
Here, we report the nature of medulloblastoma relapse 
(ie, timings, radiological patterns, and post-relapse 
outcomes), and its associations with treatment and both 
established and contemporary clinical and molecular 
features, in a cohort of patients with medulloblastoma 
who relapsed. This study encompasses all established 
disease-wide molecular features and second-generation 
MBGroup3 and MBGroup4 subtypes.2,3
Methods 
Study design and participants 
In this multicentre cohort study, patients aged 
0–18 years at diagnosis with medulloblastoma who had 
Research in context 
Evidence before this study
Relapse after conventional upfront therapies is the most adverse 
prognostic factor for childhood medulloblastoma. However, 
associations between molecular pathology at diagnosis and 
relapse characteristics are not well understood. We searched 
PubMed for articles published between Jan 1, 1990, and 
Dec 31, 2019, with the search terms “medulloblastoma”, and 
“relapse OR recurrence”. Several clinical and biology studies were 
identified and reviewed. Two initial reports have highlighted the 
clinical potential in such studies. The first investigated molecular 
subgroup at diagnosis in three independent cohorts 
(n=30, 77, and 96), and delineated subgroup-specific differences 
in relapse patterns and timings. However, findings showed 
variability between cohorts, and this study did not consider 
clinical and molecular features other than subgroup, treatment-
related differences, or the radiological patterns of distantly-
relapsed tumours. The second reported a retrospective analysis 
of a European trial for standard-risk medulloblastoma 
(HIT-SIOP-PNET4; completion 2006), describing in detail the 
patterns of disease relapse in all patients who relapsed (n=72). 
However, biological annotation at diagnosis was limited and this 
trial did not include patients at a high risk of relapse.
Added value of this study
Systematic assessment of the nature of medulloblastoma 
relapse, and its relationship to established and novel clinical 
and molecular features assessable at diagnosis and treatment 
received is essential to establish any evidence base for altered 
clinical practice. We report comprehensive investigation of the 
molecular, clinical, and radiological features, and the inter-
relationships, of a centrally reviewed cohort of 247 children 
with medulloblastoma, who relapsed after conventional 
upfront therapies. These are estimated to represent the 
relapsing component of over 800 patients, approximately 
double the size of the largest reported international 
medulloblastoma clinical trials.
Implications of all the available evidence
Our study shows the associations between the clinical and 
molecular characteristics of medulloblastoma at diagnosis, 
treatment received, and the nature of relapse and subsequent 
post-relapse disease course. The scale, clinical orientation, and 
systematic nature of our study support and challenge specific 
conclusions from previous studies and has uncovered new 
relationships. Together, these findings provide an evidence base 
to support translational opportunities aimed at improved 
disease management and outcomes, through biology-directed 
disease surveillance, post-relapse prognostication, and risk-
stratified selection of second-line treatment strategies.
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relapsed following upfront therapy were assembled from 
16 UK Children’s Cancer and Leukaemia Group insti-
tutions and four collaborating centres. Eligible pati ents 
had a confirmed diagnosis of medulloblastoma, a defined 
period of remission following upfront therapy, and a 
documented relapse on imaging or biopsy. According to 
current treatment conventions, infants (aged <3–5 years, 
cutoff depending on national treatment protocols) 
commonly received radiotherapy-sparing treatment at 
diagnosis; whereas children (aged >3–5 years) received 
conventional multimodal therapy, which included 
craniospinal irradiation.14 Therefore, we distinguished 
two restricted subcohorts for specific analyses: patients 
older than 3 years who received craniospinal irradiation 
at diagnosis (irradiated group) and patients younger than 
5 years who did not receive craniospinal irradiation (non-
irradiated group).
Pathological variant was assigned according to 
2016 WHO criteria.1 Metastatic status at diagnosis 
was determined according to Chang’s criteria.15 All 
patients in the restricted irradiated group received 
conventional radio therapy protocols (mode 36/54 Gy; 
range 24–40/50–60 Gy) following maximal safe 
neurosurgical resection. In the non-irradiated group, 
some patients received focal radio therapy (mode 54 Gy; 
range 45–55 Gy). Institutional imaging reports were 
collated and centrally reviewed by an experienced panel 
of paediatric neuro-oncologists (RMH and SB) to assess 
the degree of surgical resection (subtotal resection or 
gross total resection) and patterns of relapse. When 
interpretation of reported patterns was unclear, 
clarification was sought with the originating centre or 
clinical team. Patients with nodular relapses (defined as 
single or multiple discrete lesions) were distinguished 
from patients with diffuse (ie, diffuse leptomeningeal 
dissemination) or mixed-pattern relapses. Similarly, 
patients with local relapses were considered separately 
from patients with either distant or combined local and 
distant relapses. All patients had a documented clinical 
remission on imaging before relapse.16
Procedures
Established disease-wide molecular features either 
accepted in the WHO classification of medulloblastoma, 
or used as the current basis for treatment stratification, 
were evaluated.1 These comprised molecular subgroup 
(MBWNT, MBSHH, MBGroup3, and MBGroup4), TP53 mutation 
status, and MYC or MYCN oncogene amplification.17 
Additionally, second-generation methylation subtypes, 
isochromosome 17q, and TERT mutations were evalu ated 
as additional features with potential clinical relevance.2,3,18–20
Tumours were assigned to consensus molecular 
subgroups, as previously described using non-negative 
matrix factorisation and t-distributed stochastic neighbor 
embedding with density-based spatial clustering of 
applications with noise clustering.21 For samples with a 
low yield of DNA, the minimal methylation classifier was 
used.22 For MBGroup3 and MBGroup4 in the irradiated group, 
second-generation high-risk and low-risk subgroups 
were assigned as previously described,2 and 
subtypes I–VIII were identified according to the Group 3 
and Group 4 classifier.3 TP53 mutation status was 
assessed for exons 4–9 using established methods.4 
Entire cohort (n=247) Irradiated group 
(n=178)
Non-irradiated group 
(n=52)
Patterns of relapse
Nodular 86/187 (46%) 53/125 (42%) 23/47 (49%)
Diffuse 66/187 (35%) 46/125 (37%) 17/47 (36%)
Nodular and diffuse 35/187 (19%) 26/125 (21%) 7/47 (15%)
Local relapse 43/193 (22%) 21/129 (16%) 16/48 (33%)
Distant relapse 96/193 (50%) 73/129 (57%) 16/48 (33%)
Combined relapse 54/193 (28%) 35/129 (27%) 16/48 (33%)
Clinical features at disease relapse
Boys 175/247 (71%) 133/178 (75%) 32/52 (62%)
Girls 72/247 (29%) 45/178 (25%) 20/52 (38%)
Boys:girls ratio 2·4:1 3:1 1·6:1
Infants (<4·0 years) 38/247 (15%) 1/178 (1%) 32/52 (62%)
Children (4·0–16·0 years) 176/247 (72%) 145/178 (81%) 20/52 (38%)
Adults (>16·0 years) 33/247 (13%) 32/178 (18%) 0/52
Treatment at disease relapse
Resection 47/182 (26%) 32/124 (26%) 12/45 (27%)
Chemotherapy 128/185 (69%) 102/127 (80%) 22/46 (48%)
Craniospinal irradiation 19/188 (10%) 1/127 (1%) 15/48 (31%)
Focal radiotherapy 23/188 (12%) 18/127 (14%) 4/48 (8%)
Clinicopathological features and treatment at diagnosis
Infants (<4·0 years) 67/247 (27%) 11/178 (6%) 48/52 (92%)
Children (4·0–16·0 years) 172/247 (70%) 160/178 (90%) 4/52 (8%)
Adults (>16·0 years) 8/247 (3%) 7/178 (4%) 0/52
Subtotal resection 78/245 (32%) 58/178 (33%) 14/52 (27%)
Chemotherapy 206/243 (84%) 142/177 (80%) 49/50 (98%)
Craniospinal irradiation 187/247 (76%) 178/178 (100%) 0/178
Classic histology 158/226 (70%) 123/162 (76%) 28/48 (58%)
Large-cell anaplastic 
histology
39/226 (17%) 26/162 (16%) 8/48 (17%)
Desmoplastic/nodular 
histology
29/226 (13%) 13/162 (8%) 12/48 (25%)
Distant disease 77/238 (32%) 57/170 (34%) 13/52 (25%)
Established molecular features at diagnosis
MYC amplification 13/220 (6%) 5/157 (3%) 6/48 (13%)
MYCN amplification 24/217 (11%) 20/155 (13%) 2/47 (4%)
TP53 mutation 19/216 (9%) 18/150 (12%) 0/49
Isochromosome 17q 50/167 (30%) 40/117 (34%) 6/38 (16%)
TERT mutation 14/221 (6%) 10/162 (6%) 2/44 (5%)
MBWNT 5/216 (2%) 5/156 (3%) 0/44
MBSHH 60/216 (28%) 29/156 (19%) 25/44 (57%)
MBGroup3 62/216 (29%) 40/156 (26%) 15/44 (34%)
MBGroup4 89/216 (41%) 82/156 (53%) 4/44 (9%)
Data are n/N (%). MB=medulloblastoma. 17 patients from the entire cohort were excluded because they did not meet 
the restricted cohort criteria.
Table 1: Patterns of relapse and clinical and molecular features of the entire cohort and the two 
age-restricted subcohorts
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Copy-number assessment by interphase fluorescent in-
situ hybridisation of MYC (8q24·21 probes), MYCN 
(2p24·3 probes), and chromosome 17 imbalances 
(17p13·3 and 17q12 probes) was done as previously 
described.4 TERT promoter mutation detection 
(mutations 228C→T and 250C→T) was done according 
to previous reports.19 An additional locked nucleic acid 
probe was designed to detect the 228C→A mutation 
(TERT mut 228C→A, 5′-56FAM-CCC CAT CCG 
G-3IABkFQ-3′; Integrated DNA Technologies, Coralville, 
IO, USA). Genotyping for this mutation was done 
separately with a probe targeted to the wild type sequence 
(TERT WT, 5′-5HEX-CCC CTC CCG G-3IABkFQ-3′; 
Integrated DNA Technologies, Coralville, IO, USA) using 
the same method.
Statistical analysis 
Individual missing datapoints were missing completely 
at random. All recurrently detected (ie, occurred twice 
or more) established features were tested. 
Second-generation MBGroup3 and MBGroup4 methylation 
subtypes which were present in more than 10% of 
patients with MBGroup3 and MBGroup4 tumours treated with 
craniospinal irradiation, were also included for 
subanalyses. χ² and Fisher’s exact tests were used to 
assess associations between clinical and molecular 
features. The log-rank test was used in univariable 
analyses to assess time to relapse, time from relapse to 
death, and overall survival, and the Kaplan-Meier 
method was used to visualise results. Cox proportional-
hazards models were used to investigate the significance 
of all covariates for time to relapse, time to death after 
relapse, and overall survival in univariable and 
multivariable models, using forward likelihood-ratio 
testing. In the time to death and overall survival 
analyses, data were censored for patients who died of 
other causes or were alive with disease. We tested the 
proportionality assumption for Cox modelling using 
scaled Schoenfeld residuals. Proportional covariates 
with a raw p value of less than 0·1 in univariable 
analyses were taken forward as candidates for 
multivariable modelling. Multi variable models were 
restricted to three covariates in the entire cohort, and two 
covariates for all sub cohorts. The Benjamini-Hochberg 
procedure was used to control the false discovery rate 
and adjusted p values of less than 0·05 identified 
significant asso ciations. Analysis and visualisation was 
done using GraphPad Prism (version 8.4.1) and the 
R statistical environment (version 3.5.3).
Role of the funding source 
The funders had no role in study design, cohort 
collection, analyses, data interpretation, or writing of the 
report. RMH, ECS, GR, DW, and SCC had access to raw 
data. The corresponding author had full access to all data 
and had final responsibility for the decision to submit for 
publication.
Results 
247 patients (175 [71%] boys and 72 [29%] girls) with 
medulloblastoma relapse were included in the study 
(table 1). 17 patients were later excluded from analyses 
because they did not meet the age and treatment criteria 
for inclusion. 34 (15%) patients had tumour samples 
collected in 2010–14, 87 (37%) in 2000–09, 90 (39%) in 
1990–99, and the remaining 21 (9%) with data available 
were collected before 1990. Year of diagnosis was 
unavailable in 15 samples. All variables were assessed by 
era (before 2000 vs 2000 and after). There were no variables 
that biased planned analyses (appendix pp 2–4). As 
Figure 1: Time to relapse and survival after medulloblastoma relapse according to treatment received
(A) Time to relapse according to whether CSI was delivered at diagnosis. (B) Time from relapse to death or last 
follow-up in patients who did not receive upfront CSI, according to whether CSI was delivered at relapse. 
Ten patients were removed from time from relapse to death analysis due to: death from other cause (n=1), 
alive with disease (n=5), or missing data (n=4). CSI=craniospinal irradiation.
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expected, age and upfront treatment were confounded 
(p<0·0001; appendix p 5). Pathological variant was centrally 
assessed in 222 (90%) patients, local assessment was done 
for the remaining 25 (10%) participants (table 1).
We first characterised relapse-specific features—
including patterns of relapse (eg, nodular or diffuse 
disease) and treatment history—and established disease 
features at diagnosis in the entire cohort (table 1) and 
assessed these against time to relapse and overall survival. 
In univariable analyses of the entire cohort, upfront 
craniospinal irradiation significantly prolonged time to 
relapse (p<0·0001; figure 1A). Similarly, craniospinal 
irradiation at relapse was associated with an improved 
overall survival (p=0·0024; table 2). In 60 patients who did 
not receive upfront craniospinal irradiation, craniospinal 
irradiation at relapse was associated with survival after 
relapse (p<0·0001; figure 1B). Multivariable Cox modelling 
showed that any radiotherapy at diagnosis significantly 
increased time to relapse; whereas large-cell anaplastic 
histology and MBGroup3 tumour subgroup significantly 
decreased time to relapse. In the entire cohort, nodular 
relapses and radiotherapy at relapse significantly increased 
overall survival and MYC amplification significantly 
decreased overall survival (table 2).
Considering these radiotherapy-associated survival 
differences and the established association between age 
at diagnosis and upfront craniospinal irradiation,23 we 
divided the cohort into two groups: 178 children were 
included in the irradiated group and 52 children were 
included in the non-irradiated group (table 1). All 
Frequency Univariable analyses Multivariable analyses
Time to relapse Overall survival Time to relapse Overall survival
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Patterns of disease relapse
Nodular 86/187 (46%) ·· ·· 0·70 (0·51–0·97) 0·096 ·· ·· 0·61 (0·42–0·89) 0·010
Distant relapse 150/193 (78%) ·· ·· 1·09 (0·74–1·62) 0·78 ·· ·· ·· ··
Treatment at disease relapse
Resection 47/182 (26%) ·· ·· 0·50 (0·34–0·74) 0·0026 ·· ·· ·· ··
Chemotherapy 128/185 (69%) ·· ·· 0·70 (0·50–0·99) 0·12 ·· ·· ·· ··
Craniospinal irradiation 19/188 (10%) ·· ·· 0·29 (0·15–0·58) 0·0024 ·· ·· ·· ··
Focal radiotherapy 23/188 (12%) ·· ·· 0·64 (0·36–1·14) 0·27 ·· ·· ·· ··
Any radiotherapy 42/188 (22%) ·· ·· 0·39 (0·25–0·62) 0·00057 ·· ·· 0·40 (0·24–0·67) 0·00052
Clinicopathological features and treatment at diagnosis
Boys 175/247 (71%) 0·92 (0·70–1·22) 0·68 0·10 (0·74–1·35) 0·98 ·· ·· ·· ··
Infants (<4 years) 67/247 (27%) 1·32 (0·99–1·75) 0·15 0·84 (0·61–1·17) 0·52 ·· ·· ·· ··
Subtotal resection 78/245 (32%) 1·01 (0·77–1·32) 0·95 1·35 (1·00–1·81) 0·11 ·· ·· ·· ··
Chemotherapy 206/243 (85%) 1·15 (0·80–1·64) 0·65 1·08 (0·74–1·58) 0·77 ·· ·· ·· ··
Craniospinal irradiation 187/247 (76%) 0·52 (0·39–0·70) 0·00011 0·95 (0·68–1·34) 0·81 ·· ·· ·· ··
Focal radiotherapy 18/247 (7%) 1·05 (0·65–1·70) 0·88 1·33 (0·76–2·35) 0·50 ·· ·· ·· ··
Any radiotherapy 205/247 (83%) 0·38 (0·27–0·54) <0·0001 1·06 (0·72–1·58) 0·83 0·34 (0·23–0·50) <0·0001 ·· ··
Classic histology 158/226 (70%) 0·69 (0·52–0·92) 0·030 0·89 (0·65–1·22) 0·62 ·· ·· ·· ··
Large-cell anaplastic 
histology
39/226 (17%) 1·64 (1·16–2·33) 0·018 2·17 (1·49–3·17) 0·00083 1·62(1·12–2·34) 0·0097 ·· ··
Desmoplastic/nodular 
histology
29/226 (13%) 1·13 (0·76–1·67) 0·69 0·57 (0·36–0·91) 0·075 ·· ·· ·· ··
Distant disease 77/238 (32%) 1·19 (0·90–1·56) 0·44 1·08 (0·80–1·45) 0·76 ·· ·· ·· ··
Established molecular features at diagnosis
MYC amplification 13/220 (6%) 3·80 (2·15–6·72) <0·0001 5·39 (3·01–9·62) <0·0001 ·· ·· 6·18 (3·17–12·05) <0·0001
MYCN amplification 24/217 (11%) 1·27 (0·83–1·94) 0·50 1·69 (1·07–2·68) 0·082 ·· ·· ·· ··
TP53 mutation 19/216 (9%) 1·22 (0·76–1·96) 0·65 1·3 (0·79–2·12) 0·54 ·· ·· ·· ··
Isochromosome 17q 50/167 (30%) 0·82 (0·48–1·42) 0·70 1·17 (0·82–1·68) 0·57 ·· ·· ·· ··
TERT mutation 14/221 (6%) 0·92 (0·66–1·29) 0·66 1·17 (0·68–2·02) 0·73 ·· ·· ·· ··
MBWNT 5/216 (2%) 0·66 (0·27–1·60) 0·59 0·56 (0·14–2·27) 0·59 ·· ·· ·· ··
MBSHH 60/216 (28%) 1·32 (0·98–1·78) 0·15 0·82 (0·58–1·16) 0·50 ·· ·· ·· ··
MBGroup3 62/216 (29%) 1·82 (1·35–2·46) 0·00041 1·92 (1·40–2·65) 0·00044 1·83 (1·33–2·54) 0·00024 ·· ··
MBGroup4 89/216 (41%) 0·55 (0·41–0·72) 0·00011 0·75 (0·55–1·00) 0·12 ·· ·· ·· ··
HR=hazard ratio. MB=medulloblastoma.  
Table 2: Univariable and multivariable analyses of correlates of time to relapse and overall survival in the entire cohort
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subsequent analyses were done independently within 
these two restricted groups.
In univariable survival analyses of the irradiated 
group across all time-based measures, patients with 
MBGroup3 tumours had a shorter time to relapse (median 
1·34 years [IQR 0·99–1·89]) than did those with MBGroup4 
tumours (2·04 years [1·39–3·42]; p=0·0043; figure 2A). 
Overall, 18 (10%) of 178 patients in the irradiated group 
relapsed after 5 years surveillance; of 13 patients with 
available molecular subgroup data, eight (62%) had 
MBGroup4 tumours. Of note, no other feature examined in 
univariable analyses, including molecular features, such 
as MYCN amplification and TP53 mutation at diagnosis, 
were associated with a more rapid disease course 
(table 3). In multivariable Cox modelling, MBGroup3 and 
MYC amplification were independent adverse prognostic 
factors for time to relapse (table 3). Large-cell anaplastic 
histology and MYC amplification were independent 
adverse risk factors for overall survival. Large-cell 
anaplastic histology was associated with reduced time to 
death from relapse (appendix p 6). Of note, molecular 
subgroup was not associated with time to death from 
relapse (appendix p 6).
In univariable survival analyses of the non-irradiated 
group, high-risk features (isochromosome 17q, large-cell 
anaplastic histology, and MYC amplification) were 
associated with a more rapid time to relapse and 
subsequent poorer overall survival (appendix p 7). In 
univariable analyses, desmoplastic/nodular histology, 
MBSHH tumours, and craniospinal irradiation at relapse 
were associated with a sustained overall survival 
(appendix p 7). In multivariable Cox modelling, 
MYC amplification and large-cell anaplastic histology 
(appendix p 7) were significant independent risk factors for 
reduced time to relapse whereas desmoplastic/nodular 
histology (hazard ratio [HR] 0·23, 95% CI 0·07–0·77) and 
craniospinal irradiation at relapse were significantly 
associated with increased time to death after relapse (0·27, 
0·11–0·68; appendix p 7). MYC amplification was a 
significant independent risk factor for decreased overall 
survival (23·52, 4·85–114·05); however, resection at relapse 
was associated with longer overall survival (0·17, 
0·05–0·57; appendix p 7).
Nine (5%) of 178 patients in the irradiated group survived 
their relapse. Median follow-up after relapse was 4·72 years 
(IQR 3·54–10·15), with no common factors observed in 
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Figure 2: Time to relapse and pattern of relapse according to molecular 
subgroup in the irradiated group
(A) Time to relapse in the four consensus molecular subgroups in patients who 
received upfront CSI (irradiated group). (B) Schematic representing the patients 
with distant disease at diagnosis, emergent distant disease at relapse, and 
distant disease at relapse according to molecular subgroup. (C) Different 
patterns of relapsed disease according to molecular subgroup and relapse 
pattern. MBSHH=19 patients, MBGroup3=25 patients, MBGroup4=58 patients. 
CSI=craniospinal irradiation. MB=medulloblastoma.
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these survivors (appendix p 8). 11 (21%) of 52 patients 
in the non-irradiated group survived their relapse, 
with a median follow-up after relapse of 7·56 years 
(6·15–15·40 appendix p 8). Consistent with univariable 
survival analyses (appendix p 7), desmoplastic/nodular 
histology was the most frequently observed histological 
subtype in survivors in this group (seven [64%] of 
11 patients); most survivors received craniospinal 
irradiation (eight [73%] of 11 patients) and had re-resection 
(six [60%] of ten patients with available data) at relapse. 
The seven survivors with tumours with desmoplastic/
nodular histology were MBSHH (MBSHH-DN ; appendix p 8). 
Overall, seven [64%] of 11 patients with MBSHH-DN tumours 
survived their relapse. Of these seven survivors with 
MBSHH-DN tumours, all received radiotherapy at relapse 
(five received craniospinal irradiation and two received 
focal irradiation; appendix p 8). Of note, of the four patients 
with MBSHH-DN who died, two had data on their treatment 
history available; both patients did not receive any 
radiotherapy at relapse.
Patterns of disease relapse were also molecular 
subgroup dependent in the irradiated group. Isolated 
local relapses were most commonly observed in patients 
with MBSHH tumours (seven [35%] of 20 relapses; 
p=0·0028); whereas, patients with MBGroup3 and MBGroup4 
tumours had predominantly distant relapses (figure 2B). 
Although distant relapses were also predominant in 
patients with MBSHH tumours (13 [65%] of 20 relapses), 
these were at a significantly lower frequency than in 
patients with MBGroup3 tumours (23 [92%] of 25) and 
MBGroup4 tumours (56 [90%] of 62; p=0·011; figure 2B). 
However, rates of emergence of distant disease at relapse 
in the irradiated group did not differ between molecular 
subgroups (p=0·19; figure 2B). Approximately 80% of all 
patients with local-only disease at diagnosis displayed 
emergent distant disease at relapse (figure 2B).
Of the 20 isolated local relapses, 19 were significantly 
associated with nodular disease (p<0·0001; appendix p 5). 
However, although patients who locally relapsed with 
MBSHH tumours were significantly associated with nodular 
disease (p=0·016; appendix p 5) this finding was not true 
for patients who locally relapsed with MBGroup3 and MBGroup4 
tumours, because of their differing patterns of distant 
relapse. Patients with MBSHH, MBGroup3, and MBGroup4 
tumours all had distant-diffuse relapses (figure 2C). 
However, distant nodular relapses were almost exclusively 
observed in patients with MBGroup3 and MBGroup4 tumours 
(figure 2C). Furthermore, in post-hoc exploratory 
analyses, nine (82%) of 11 patients with distantly relapsed 
diffuse MBSHH tumours had MYCN amplification at 
diagnosis, compared with two [25%] of eight patients with 
nodular MBSHH relapses (p=0·024; appendix p 5). Distant 
diffuse patterns were associated with early relapses 
(within 18 months of initial diagnosis) in patients in the 
irradiated group with MBGroup3 tumours (p=0·0048; 
appendix p 5), this association was not observed in 
patients with MBSHH or MBGroup4 tumours.
Subgroup-specific patterns of relapse were also 
observed in the non-irradiated group. Patients with 
MBSHH (p<0·0001) and MBGroup3 (p=0·060) tumours 
acquired distant relapses (appendix p 9) and had 
predominantly distant disease at relapse (17 [71%] of 
24 MBSHH tumours and 12 [80%] of 15 MBGroup3 tumours; 
appendix p 9). MBSHH and MBGroup3 displayed similar 
proportions of distant-diffuse and distant-nodular 
relapses (p=0·71; appendix p 9); local-nodular relapses 
were more commonly observed in patients with MBSHH 
tumours (appendix p 9).
Exploratory analyses of second-generation molecular 
subtypes within MBGroup3 and MBGroup4 in the irradiated 
group showed further insights into the patterns and 
timings of relapse. Analyses of MBGroup3 and MBGroup4 
subtypes I–VIII (figure 3A) in 90 patients revealed a 
differing disease course between subtypes (time to 
relapse p<0·0001; time from relapse to death p=0·00012; 
and overall survival p=0·0086; figure 3B; appendix p 10). 
For example, group II, associated with MBGroup3 and 
MYC amplification, showed the shortest time to death 
after relapse (median 0·26 years [0·09–0·55], p=0·0063; 
appendix p 11). Similar to the consensus MBGroup3 and 
MBGroup4 molecular subgroups,, subtypes II (p=0·0098), 
III (p=0·0046), and VIII (p<0·0001) developed distant 
disease at relapse whereas subtypes V (p=0·32) and 
VII (p=0·16) maintained their distant disease status 
between diagnosis and relapse (table 4). However, 
patterns of distant disease at relapse did not differ 
significantly between subtypes (figure 3C).
Frequency Univariable analyses Multivariable analyses
HR (95% CI) p value  HR (95% CI) p value
Clinicopathological features and treatment at diagnosis
Boys 133/178 (75%) 0·98 (0·69–1·38) 0·90 ·· ··
Subtotal resection 58/178 (33%) 0·92 (0·67–1·27) 0·84 ·· ··
Chemotherapy 142/177 (80%) 1·06 (0·72–1·54) 0·83 ·· ··
Classic histology 123/162 (76%) 0·83 (0·58–1·19) 0·71 ·· ··
Large-cell anaplastic 
histology
26/162 (16%) 1·42 (0·93–2·18) 0·43 ·· ··
Desmoplastic/
nodular histology
13/162 (8%) 0·89 (0·50–1·58) 0·79 ·· ··
Distant disease 57/170 (34%) 1·29 (0·93–1·78) 0·39 ·· ··
Established molecular features at diagnosis
MYC amplification 5/157 (3%) 3·13 (1·27–7·68) 0·069 16·77 (5·37–52·45) <0·0001
MYCN amplification 20/155 (13%) 1·28 (0·80–2·05) 0·63 ·· ··
TP53 mutation 18/150 (12%) 1·40 (0·85–2·31) 0·51 ·· ··
Isochromosome 17q 40/117 (34%) 0·87 (0·59–1·28) 0·78 ·· ··
TERT mutation 10/162 (6%) 0·76 (0·40–1·46) 0·73 ·· ··
MBWNT 5/156 (3%) 0·75 (0·31–1·84) 0·77 ·· ··
MBSHH 29/156 (19%) 1·10 (0·73–1·65) 0·79 ·· ··
MBGroup3 40/156 (26%) 1·88 (1·30–2·72) 0·012 1·77 (1·21–2·59) 0·0031
MBGroup4 82/156 (53%) 0·65 (0·47–0·89) 0·063 ·· ··
HR=hazard ratio. MB=medulloblastoma.
Table 3: Univariable and multivariable analyses of correlates of time to relapse in the irradiated group
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Evaluating the methylation subtypes described by 
Schwalbe and colleagues,2 MBGroup3-HR had a rapid disease 
course (time to relapse p<0·0001; time from relapse to 
death p=0·0011; overall survival p<0·0001; appendix p 12). 
Rates of emergent distant disease at relapse were similar 
across subtypes (appendix p 12). In multivariable analyses 
of the irradiated MBGroup3 and MBGroup4 tumours, MBGroup4-HR 
had increased time to relapse whereas subtype III had 
decreased time to relapse (appendix p 11). Subtype II was 
associated with a rapid disease course after relapse 
(appendix p 11), whereas nodular disease at relapse 
was associated with a  prolonged time from relapse 
to death (HR 0·42, 0·21–0·81). Finally, MBGroup3-HR and 
MYC amplification were associated adversely with overall 
survival (appendix p 11).
Discussion 
We have presented the largest study of the nature and 
correlates of disease relapse in patients with medullo-
blastoma. Our results suggest that treatment and 
molecular subgroup are associated with the nature of 
relapse and subsequent disease course. These findings 
can help to inform disease management through 
improved post-therapy surveillance and post-relapse 
prognostication.
In the irradiated group, disease course varies according 
to molecular subgroup; patients with MBGroup4 tumours 
were associated with a prolonged time to relapse 
(appendix p 14) and consequently warrant a prolonged 
surveillance period of up to 10 years. Furthermore, patterns 
of relapse were molecular subgroup dependent. Local-
nodular relapses were more common in MBSHH tumours as 
previously reported.5 However, MBSHH, MBGroup3, and 
MBGroup4 molecular subgroups all developed a significant 
percentage of distant relapses. Of note, this finding does 
not support suggestions by others to intensify the local 
radiotherapy boost delivered to patients with MBSHH 
tumours at diagnosis to reduce relapse rates; isolated local 
MBSHH relapses in our cohort were in the minority.5
Our study details the subgroup specific patterns of 
distant relapse that can aid both disease surveillance and 
post-relapse prognostication (appendix p 14). Following 
craniospinal irradiation, distantly relapsed MBSHH almost 
exclusively displayed diffuse disease, which is associated 
with MYCN amplification at diagnosis. Therefore, 
MRI surveillance after initial treatment of patients with 
MYCN amplified MBSHH should always consider the 
whole neuroaxis, even if the patient had local-only 
disease at diagnosis. Distantly relapsed MBGroup3 and 
MBGroup4 tumours displayed both nodular and diffuse 
patterns of disease. Nodular relapse was associated with 
prolonged survival post-relapse in patients with MBGroup3 
Figure 3: Assessment of relapse characteristics by second-generation MBGroup3 
and MBGroup4 subtypes
(A) Sankey plot of the relationship between consensus MBGroup3 and MBGroup4 and 
second-generation subtypes I–VIII. (B) Time to relapse according to second-
generation MBGroup3 and MBGroup4 molecular subtype. (C) The different patterns of 
relapsed disease according to second-generation MBGroup3 and MBGroup4 molecular 
subtype. Subtype II=9 patients. Subtype III=8 patients. Subtype V=7 patients. 
Subtype VII=8 patients. Subtype VIII=22 patients. MB=medulloblastoma.
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and MBGroup4 tumours. Together, these findings should be 
used to inform clinical discussions and treatment 
decisions. For example, nodular disease is more 
amenable to local therapy strategies (re-resection and 
focal irradiation), which might be justified given this new 
evidence of their prolonged survival after relapse.
Patients not treated with upfront craniospinal 
irradiation relapsed quickly, with more than half of all 
children relapsing within 18 months of initial diagnosis. 
This rapid disease course is compounded by the presence 
of recognised high-risk features (eg, MYC amplification 
and large-cell anaplastic histology) that inform current 
clinical management. However, patterns of distantly-
relapsed non-irradiated MBSHH and MBGroup3 tumours 
differed to those observed in the irradiated group and 
were not associated with disease course after relapse. 
Treatment at relapse (eg, craniospinal irradiation at 
relapse and re-resection), MBSHH, and desmoplastic/
nodular histology were associated with a more favourable 
disease course after relapse. Together, these findings 
inform counselling at diagnosis and relapse, identifying 
a subcohort of patients with potentially salvageable 
disease should it relapse (appendix p 14).
Finally, analyses of novel second-generation molecular 
subtypes suggest specific subtypes further resolve the 
heterogeneous nature of MBGroup3 and MBGroup4 relapses 
after treatment with craniospinal irradiation. For example 
subtype II tumours displayed a rapid time to death after 
relapse. These findings emphasise the importance of 
understanding tumour biology at diagnosis, how this 
relates to the nature of disease relapse and underlying 
mechanisms, and, in the future, how these could 
influence prognostication after relapse.
However, this study does have some limitations. 
Although the study is retrospective and is not based on a 
uniformly treated clinical trial cohort, all patients were 
managed using current contemporary treatment strategies 
appropriate to their age. Of note, we considered the 
retrospective nature of this cohort in our assessments; no 
variable or outcome measure was biased by treatment era 
(before 2000 vs 2000 and after). To allow us to answer the 
study questions, only patients who relapsed with disease 
were selected for this study. Overall, we estimate our 
cohort comprises approximately 50% of all patients (aged 
up to 18 years) in the UK with medullo blastoma relapse 
during the study collection period. By contrast to all 
previous studies,5,7 we have considered upfront-treatment 
differences, and analysed the patterns and timings of 
relapse in conjunction with detailed annotation of all 
established disease-wide features at dia gnosis and novel 
second-generation methylation subtypes.
In summary, consideration of upfront diagnostic disease 
features, coupled with time and pattern of relapse, offers 
opportunities to improve the clinical management of 
medulloblastoma.
Contributors 
RMH, SB, and SCC conceived of and designed the study. RMH, SR, DH, 
JCL, and SC did the laboratory experimentation and analysis. RMH and 
ECS did the statistical analysis. RMH, ECS, GR, and DW did the 
bioinformatics analysis. RMH, ECS, and YG prepared the figures. 
SBW, TSJ, and AJ did the central pathological review. RMH, SBW, TSJ, 
AM, AJ, BP, and SB provided patient data and clinical interpretation. 
All authors are accountable for all aspects of the work and approved the 
final copy.
Declaration of interest
TSJ reports grants from the National Institute of Health Research 
during the study; grants from Cancer Research UK and Olivia Hodson 
Cancer Fund outside the submitted work; and is a director and 
shareholder of Repath and Neuropath. All other authors declare no 
competing interests.
Acknowledgments
This study was funded by Cancer Research UK, Action Medical 
Research, The Tom Grahame Trust, The JGW Patterson Foundation, 
Star for Harris, The Institute of Child Health - Newcastle University - 
Institute of Child Health High-Risk Childhood Brain Tumour Network 
(co-funded by The Brain Tumour Charity, Great Ormond Street 
Children’s Charity, and Children with Cancer UK).
References 
1 Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health 
Organization classification of tumors of the central nervous system: 
a summary. Acta Neuropathologica 2016; 131: 803–20.
2 Schwalbe EC, Lindey JC, Nakjang S, et al. Novel molecular 
subgroups for clinical classification and outcome prediction in 
childhood medulloblastoma: a cohort study. Lancet Oncol 2017; 
18: 958–71.
3 Sharma T, Schwalbe EC, Williamson D, et al. Second-generation 
molecular subgrouping of medulloblastoma: an international meta-
analysis of group 3 and group 4 subtypes. Acta Neuropathologica 
2019; 138: 309–26.
4 Hill RM, Kuijper S, Lindsey JC, et al. Combined MYC and P53 
defects emerge at medulloblastoma relapse and define rapidly 
progressive, therapeutically targetable disease. Cancer Cell 2015 
27: 72–84.
5 Ramaswamy V, Remke M, Bouffet E, et al. Recurrence patterns 
across medulloblastoma subgroups: an integrated clinical and 
molecular analysis. Lancet Oncol 2013; 14: 1200–07.
6 Pizer B, Donachie PHJ, Robinson K, et al. Treatment of recurrent 
central nervous system primitive neuroectodermal tumours in 
children and adolescents: results of a Children’s Cancer and 
Leukaemia Group study. Eur J Cancer 2011; 47: 1389–97.
7 Sabel M, Fleischhack G, Tippelt S, et al. Relapse patterns and 
outcome after relapse in standard risk medulloblastoma: a report 
from the HIT-SIOP-PNET4 study. J Neurooncol 2016; 129: 515–24.
8 Muller K, Mynarek M, Zwiener I, et al. Postponed is not canceled: 
role of craniospinal radiation therapy in the management of recurrent 
infant medulloblastoma—an experience from the HIT-REZ 1997 & 
2005 studies. Int J Radiat Oncol Biol Phys 2014; 88: 1019–24.
Distant disease 
at diagnosis*
Distant disease 
at relapse†
p value‡ Acquired distant 
disease§
II 3/11 (27%) 8/9 (89%) 0·0098 6/7 (86%)
III 4/13 (31%) 8/8 (100%) 0·0046 7/7 (100%)
V 6/11 (55%) 6/7 (86%) 0·32 3/4 (75%)
VII 6/12 (50%) 7/8 (87%) 0·16 2/3 (67%)
VIII 6/27 (22%) 22/24 (92%) <0·0001 17/19 (89%)
Only MBGroup3 and MBGroup4 subtypes present in >10% of cohort included in analyses 
(I, IV, and VI excluded from analyses). MB=medulloblastoma. *No significant 
difference by molecular subtype p=0·25. †No significant difference by molecular 
subtype p=0·88. ‡p value comparing the proportion of distant disease at 
diagnosis versus distant disease at relapse within MBGroup3 and MBGroup4 second-
generation subtypes. §No significant difference by molecular subtype p=0·58. 
Table 4: The prevalence of distant disease at diagnosis and distant 
disease acquired at relapse according to second-generation MBGroup3 and 
MBGroup4 molecular subtype
Articles
10 www.thelancet.com/child-adolescent   Published online October 22, 2020    https://doi.org/10.1016/S2352-4642(20)30246-7
9 Rutkowski S, Gerber NU, von Hoff K, et al. Treatment of early 
childhood medulloblastoma by postoperative chemotherapy and 
deferred radiotherapy. Neuro Oncol 2009; 11: 201–10.
10 Aguilera D, Mazewski C, Fangusaro J, et al. Response to 
bevacizumab, irinotecan, and temozolomide in children with 
relapsed medulloblastoma: a multi-institutional experience. 
Childs Nerv Syst 2013; 29: 589–96.
11 Wetmore C, Herington D, Lin T, et al. Reirradiation of recurrent 
medulloblastoma: does clinical benefit outweigh risk for toxicity? 
Cancer 2014; 120: 3731–37.
12 Sterba J, Pavelka Z, Andre N, et al. Second complete remission of 
relapsed medulloblastoma induced by metronomic chemotherapy. 
Pediatric Blood Cancer 2010; 54: 616–17.
13 Peyrl A, Chocholous M, Kieran MW, et al. Antiangiogenic 
metronomic therapy for children with recurrent embryonal brain 
tumors. Pediatric Blood Cancer 2012; 59: 511–17.
14 Northcott PA, Robinson GW, Kratz CP, et al. Medulloblastoma. 
Nat Rev Dis Primers 2019; 5: 11.
15 Chang CH, Housepian EM, Herbert C Jr. An operative staging 
system and a megavoltage radiotherapeutic technic for cerebellar 
medulloblastomas. Radiology 1969; 93: 1351–59.
16 Dufour C, Beaugrand A, Pizer B, et al. Metastatic medulloblastoma 
in childhood: Chang’s classification revisited. Int J Surg Oncol 2012; 
2012: 245385.
17 Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of 
childhood medulloblastoma in the molecular era: the current 
consensus. Acta Neuropathologica 2016; 131: 821–31.
18 Shih DJ, et al. Cytogenetic prognostication within medulloblastoma 
subgroups. J Clin Oncol 2014; 32: 886–96.
19 Remke M, Ramaswamy V, Peacock J, et al. TERT promoter 
mutations are highly recurrent in SHH subgroup medulloblastoma. 
Acta Neuropathologica 2013; 126: 917–29.
20 Lindsey JC, et al. TERT promoter mutation and aberrant 
hypermethylation are associated with elevated expression in 
medulloblastoma and characterise the majority of non-infant SHH 
subgroup tumours. Acta Neuropathologica 2014; 127: 307–09.
21 Schwalbe EC, Williamson D, Lindsey JC, et al. DNA methylation 
profiling of medulloblastoma allows robust subclassification and 
improved outcome prediction using formalin-fixed biopsies. 
Acta Neuropathologica 2013; 125: 359–71.
22 Schwalbe EC, Hicks D, Rafiee G, et al. Minimal methylation 
classifier (MIMIC): a novel method for derivation and rapid 
diagnostic detection of disease-associated DNA methylation 
signatures. Sci Rep 2017; 7: 13421.
23 Robinson GW, Rudneva VA, Buchhalter I, et al. Risk-adapted 
therapy for young children with medulloblastoma (SJYC07): 
therapeutic and molecular outcomes from a multicentre, phase 2 
trial. Lancet Oncol 2018; 19: 768–84.
